海普瑞(09989.HK):預期君聖泰將於12月22日開始於聯交所主板買賣
格隆匯12月18日丨海普瑞(09989.HK)發佈公吿,有關君聖泰醫藥(“君聖泰”)的股份擬於聯交所主板發售及上市。於本公吿日期,公司持有君聖泰已發行股本總額約24.06%權益,而君聖泰為公司的聯營公司。君聖泰已就建議發售及上市刊發日期為2023年12月14日的招股章程。待達成建議發售及上市的先決條件(包括有關包銷協議並無被終止及聯交所已授出所需上市批准)後,目前預期君聖泰的股份將於2023年12月22日開始於聯交所主板買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.